Since the commercial anti-HLA-E mAbs, particularly those most commonly used on human cancer tissues such as MEM-E/02 and 3D12 (Table 5), do not meet the critical requirement of monospecificity of the mAb, they may not be considered reliable for specific immunorecognition of HLA-E on human cancer tissues. The gene discussed is HLA-E; the disease is cancer.